Renal DOAC Guidance: Dosing adjustment thresholds based on Cockcroft-Gault. Accuracy is critical as renal clearance varies from 25% (Apixaban) to 80% (Dabigatran).
CrCl (mL/min) — Cockcroft-Gault
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Adjusting DOAC therapy in patients with varying degrees of chronic kidney disease (CKD).
Identifying contraindications based on Cockcroft-Gault Creatinine Clearance (CrCl).
Applying dose-reduction rules specifically for renal impairment.
Methodology
Use Cockcroft-Gault using ACTUAL body weight for all DOAC dosing decisions. Do not use eGFR (MDRD/CKD-EPI) as the DOAC registrational trials were based on CrCl.
Section 2
Formula & Logic
Renal Dose Adjustment Grid
Agent
CrCl > 50
CrCl 15 - 50
CrCl < 15
Dabigatran
150 mg bid
Reduce/Stop (30-50)
Contraindicated
Rivaroxaban
20 mg qd
15 mg qd
Contraindicated
Apixaban
5 mg bid
5 mg bid (unless AF rule)
Not well studied
Edoxaban
60 mg qd
30 mg qd
Contraindicated
The Edoxaban Floor/Ceiling
In Atrial Fibrillation, Edoxaban is NOT recommended if CrCl > 95 mL/min due to potentially reduced efficacy.
Section 3
Pearls/Pitfalls
Dabigatran Renal Risk
Dabigatran is ~80% renally cleared (the highest of all DOACs). A sudden drop in renal function (e.g., due to dehydration or NSAID use) can lead to rapid accumulation and catastrophic bleeding.
Apixaban in HD
While the FDA has approved Apixaban for use in hemodialysis (HD) at 5mg bid (or 2.5mg if age/weight rules met), many societies (EHRA) still recommend extreme caution or Vitamin K Antagonists for this population.
Section 4
Evidence Appraisal
Primary Consensus
The 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Steffel J et al. • Europace. 2021;23(10):1612-1676.
Standardized by the EHRA to prevent the "Dose Reduction Paradox"—where clinicians reflexively reduce doses without meeting criteria, leading to subtherapeutic levels and preventable strokes.